Risk factors for indinavir-associated urological symptoms

Gespeichert in:

Format:	E-Artikel
Sprache:	Englisch

Erschienen:	2002

Schlagwörter:	Indinavir Nephrolithiasis Urologic Symptom Prior Change Protease Inhibitor Treatment

Anmerkung:	© Adis International Ltd 2002

Übergeordnetes Werk:	Enthalten in: Inpharma weekly - Auckland : ADIS internat., 1975, 1349(2002), 1 vom: Aug., Seite 21-21
Übergeordnetes Werk:	volume:1349 ; year:2002 ; number:1 ; month:08 ; pages:21-21

Links:	Volltext

DOI / URN:	10.2165/00128413-200213490-00054

Katalog-ID:	SPR035135522

Internformat


LEADER	01000caa a22002652 4500
001	SPR035135522
003	DE-627
005	20230519203411.0
007	cr uuu---uuuuu
008	201007s2002 xx \|\|\|\|\|o 00\| \|\|eng c
024	7		\|a 10.2165/00128413-200213490-00054 \|2 doi
035			\|a (DE-627)SPR035135522
035			\|a (SPR)00128413-200213490-00054-e
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a eng
245	1	0	\|a Risk factors for indinavir-associated urological symptoms
264		1	\|c 2002
336			\|a Text \|b txt \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
500			\|a © Adis International Ltd 2002
650		4	\|a Indinavir \|7 (dpeaa)DE-He213
650		4	\|a Nephrolithiasis \|7 (dpeaa)DE-He213
650		4	\|a Urologic Symptom \|7 (dpeaa)DE-He213
650		4	\|a Prior Change \|7 (dpeaa)DE-He213
650		4	\|a Protease Inhibitor Treatment \|7 (dpeaa)DE-He213
773	0	8	\|i Enthalten in \|t Inpharma weekly \|d Auckland : ADIS internat., 1975 \|g 1349(2002), 1 vom: Aug., Seite 21-21 \|w (DE-627)373977859 \|w (DE-600)2127607-9 \|x 2230-6056 \|7 nnns
773	1	8	\|g volume:1349 \|g year:2002 \|g number:1 \|g month:08 \|g pages:21-21
856	4	0	\|u https://dx.doi.org/10.2165/00128413-200213490-00054 \|z lizenzpflichtig \|3 Volltext
912			\|a GBV_USEFLAG_A
912			\|a SYSFLAG_A
912			\|a GBV_SPRINGER
912			\|a SSG-OLC-PHA
912			\|a GBV_ILN_20
951			\|a AR
952			\|d 1349 \|j 2002 \|e 1 \|c 08 \|h 21-21

Indexfelder

matchkey_str	article:22306056:2002----::ikatrfrniaiascaeuo
hierarchy_sort_str	2002
publishDate	2002
allfields	10.2165/00128413-200213490-00054 doi (DE-627)SPR035135522 (SPR)00128413-200213490-00054-e DE-627 ger DE-627 rakwb eng Risk factors for indinavir-associated urological symptoms 2002 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © Adis International Ltd 2002 Indinavir (dpeaa)DE-He213 Nephrolithiasis (dpeaa)DE-He213 Urologic Symptom (dpeaa)DE-He213 Prior Change (dpeaa)DE-He213 Protease Inhibitor Treatment (dpeaa)DE-He213 Enthalten in Inpharma weekly Auckland : ADIS internat., 1975 1349(2002), 1 vom: Aug., Seite 21-21 (DE-627)373977859 (DE-600)2127607-9 2230-6056 nnns volume:1349 year:2002 number:1 month:08 pages:21-21 https://dx.doi.org/10.2165/00128413-200213490-00054 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_20 AR 1349 2002 1 08 21-21
spelling	10.2165/00128413-200213490-00054 doi (DE-627)SPR035135522 (SPR)00128413-200213490-00054-e DE-627 ger DE-627 rakwb eng Risk factors for indinavir-associated urological symptoms 2002 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © Adis International Ltd 2002 Indinavir (dpeaa)DE-He213 Nephrolithiasis (dpeaa)DE-He213 Urologic Symptom (dpeaa)DE-He213 Prior Change (dpeaa)DE-He213 Protease Inhibitor Treatment (dpeaa)DE-He213 Enthalten in Inpharma weekly Auckland : ADIS internat., 1975 1349(2002), 1 vom: Aug., Seite 21-21 (DE-627)373977859 (DE-600)2127607-9 2230-6056 nnns volume:1349 year:2002 number:1 month:08 pages:21-21 https://dx.doi.org/10.2165/00128413-200213490-00054 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_20 AR 1349 2002 1 08 21-21
allfields_unstemmed	10.2165/00128413-200213490-00054 doi (DE-627)SPR035135522 (SPR)00128413-200213490-00054-e DE-627 ger DE-627 rakwb eng Risk factors for indinavir-associated urological symptoms 2002 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © Adis International Ltd 2002 Indinavir (dpeaa)DE-He213 Nephrolithiasis (dpeaa)DE-He213 Urologic Symptom (dpeaa)DE-He213 Prior Change (dpeaa)DE-He213 Protease Inhibitor Treatment (dpeaa)DE-He213 Enthalten in Inpharma weekly Auckland : ADIS internat., 1975 1349(2002), 1 vom: Aug., Seite 21-21 (DE-627)373977859 (DE-600)2127607-9 2230-6056 nnns volume:1349 year:2002 number:1 month:08 pages:21-21 https://dx.doi.org/10.2165/00128413-200213490-00054 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_20 AR 1349 2002 1 08 21-21
allfieldsGer	10.2165/00128413-200213490-00054 doi (DE-627)SPR035135522 (SPR)00128413-200213490-00054-e DE-627 ger DE-627 rakwb eng Risk factors for indinavir-associated urological symptoms 2002 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © Adis International Ltd 2002 Indinavir (dpeaa)DE-He213 Nephrolithiasis (dpeaa)DE-He213 Urologic Symptom (dpeaa)DE-He213 Prior Change (dpeaa)DE-He213 Protease Inhibitor Treatment (dpeaa)DE-He213 Enthalten in Inpharma weekly Auckland : ADIS internat., 1975 1349(2002), 1 vom: Aug., Seite 21-21 (DE-627)373977859 (DE-600)2127607-9 2230-6056 nnns volume:1349 year:2002 number:1 month:08 pages:21-21 https://dx.doi.org/10.2165/00128413-200213490-00054 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_20 AR 1349 2002 1 08 21-21
allfieldsSound	10.2165/00128413-200213490-00054 doi (DE-627)SPR035135522 (SPR)00128413-200213490-00054-e DE-627 ger DE-627 rakwb eng Risk factors for indinavir-associated urological symptoms 2002 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © Adis International Ltd 2002 Indinavir (dpeaa)DE-He213 Nephrolithiasis (dpeaa)DE-He213 Urologic Symptom (dpeaa)DE-He213 Prior Change (dpeaa)DE-He213 Protease Inhibitor Treatment (dpeaa)DE-He213 Enthalten in Inpharma weekly Auckland : ADIS internat., 1975 1349(2002), 1 vom: Aug., Seite 21-21 (DE-627)373977859 (DE-600)2127607-9 2230-6056 nnns volume:1349 year:2002 number:1 month:08 pages:21-21 https://dx.doi.org/10.2165/00128413-200213490-00054 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_20 AR 1349 2002 1 08 21-21
language	English
source	Enthalten in Inpharma weekly 1349(2002), 1 vom: Aug., Seite 21-21 volume:1349 year:2002 number:1 month:08 pages:21-21
sourceStr	Enthalten in Inpharma weekly 1349(2002), 1 vom: Aug., Seite 21-21 volume:1349 year:2002 number:1 month:08 pages:21-21
format_phy_str_mv	Article
institution	findex.gbv.de
topic_facet	Indinavir Nephrolithiasis Urologic Symptom Prior Change Protease Inhibitor Treatment
isfreeaccess_bool	false
container_title	Inpharma weekly
publishDateDaySort_date	2002-08-01T00:00:00Z
hierarchy_top_id	373977859
id	SPR035135522
language_de	englisch
fullrecord	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR035135522</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230519203411.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">201007s2002 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.2165/00128413-200213490-00054</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR035135522</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)00128413-200213490-00054-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Risk factors for indinavir-associated urological symptoms</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2002</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">© Adis International Ltd 2002</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Indinavir</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Nephrolithiasis</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Urologic Symptom</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Prior Change</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Protease Inhibitor Treatment</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Inpharma weekly</subfield><subfield code="d">Auckland : ADIS internat., 1975</subfield><subfield code="g">1349(2002), 1 vom: Aug., Seite 21-21</subfield><subfield code="w">(DE-627)373977859</subfield><subfield code="w">(DE-600)2127607-9</subfield><subfield code="x">2230-6056</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:1349</subfield><subfield code="g">year:2002</subfield><subfield code="g">number:1</subfield><subfield code="g">month:08</subfield><subfield code="g">pages:21-21</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.2165/00128413-200213490-00054</subfield><subfield code="z">lizenzpflichtig</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">1349</subfield><subfield code="j">2002</subfield><subfield code="e">1</subfield><subfield code="c">08</subfield><subfield code="h">21-21</subfield></datafield></record></collection>
ppnlink_with_tag_str_mv	@@773@@(DE-627)373977859
format	electronic Article
delete_txt_mv	keep
collection	springer
remote_str	true
illustrated	Not Illustrated
issn	2230-6056
topic_title	Risk factors for indinavir-associated urological symptoms Indinavir (dpeaa)DE-He213 Nephrolithiasis (dpeaa)DE-He213 Urologic Symptom (dpeaa)DE-He213 Prior Change (dpeaa)DE-He213 Protease Inhibitor Treatment (dpeaa)DE-He213
topic	misc Indinavir misc Nephrolithiasis misc Urologic Symptom misc Prior Change misc Protease Inhibitor Treatment
spellingShingle	misc Indinavir misc Nephrolithiasis misc Urologic Symptom misc Prior Change misc Protease Inhibitor Treatment Risk factors for indinavir-associated urological symptoms
topic_unstemmed	misc Indinavir misc Nephrolithiasis misc Urologic Symptom misc Prior Change misc Protease Inhibitor Treatment
topic_browse	misc Indinavir misc Nephrolithiasis misc Urologic Symptom misc Prior Change misc Protease Inhibitor Treatment
format_facet	Elektronische Aufsätze Aufsätze Elektronische Ressource
format_main_str_mv	Text Zeitschrift/Artikel
carriertype_str_mv	cr
hierarchy_parent_title	Inpharma weekly
hierarchy_parent_id	373977859
hierarchy_top_title	Inpharma weekly
isfreeaccess_txt	false
familylinks_str_mv	(DE-627)373977859 (DE-600)2127607-9
title	Risk factors for indinavir-associated urological symptoms
ctrlnum	(DE-627)SPR035135522 (SPR)00128413-200213490-00054-e
title_full	Risk factors for indinavir-associated urological symptoms
journal	Inpharma weekly
journalStr	Inpharma weekly
lang_code	eng
isOA_bool	false
recordtype	marc
publishDateSort	2002
contenttype_str_mv	txt
container_start_page	21
container_volume	1349
format_se	Elektronische Aufsätze
doi_str_mv	10.2165/00128413-200213490-00054
title_sort	risk factors for indinavir-associated urological symptoms
title_auth	Risk factors for indinavir-associated urological symptoms
abstract	© Adis International Ltd 2002
abstractGer	© Adis International Ltd 2002
abstract_unstemmed	© Adis International Ltd 2002
collection_details	GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_20
container_issue	1
title_short	Risk factors for indinavir-associated urological symptoms
url	https://dx.doi.org/10.2165/00128413-200213490-00054
remote_bool	true
ppnlink	373977859
mediatype_str_mv	c
isOA_txt	false
hochschulschrift_bool	false
doi_str	10.2165/00128413-200213490-00054
up_date	2024-07-03T13:43:05.820Z
_version_	1803565594917732352
fullrecord_marcxml	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR035135522</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230519203411.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">201007s2002 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.2165/00128413-200213490-00054</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR035135522</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)00128413-200213490-00054-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Risk factors for indinavir-associated urological symptoms</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2002</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">© Adis International Ltd 2002</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Indinavir</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Nephrolithiasis</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Urologic Symptom</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Prior Change</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Protease Inhibitor Treatment</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Inpharma weekly</subfield><subfield code="d">Auckland : ADIS internat., 1975</subfield><subfield code="g">1349(2002), 1 vom: Aug., Seite 21-21</subfield><subfield code="w">(DE-627)373977859</subfield><subfield code="w">(DE-600)2127607-9</subfield><subfield code="x">2230-6056</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:1349</subfield><subfield code="g">year:2002</subfield><subfield code="g">number:1</subfield><subfield code="g">month:08</subfield><subfield code="g">pages:21-21</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.2165/00128413-200213490-00054</subfield><subfield code="z">lizenzpflichtig</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">1349</subfield><subfield code="j">2002</subfield><subfield code="e">1</subfield><subfield code="c">08</subfield><subfield code="h">21-21</subfield></datafield></record></collection>
score	7.4015017

Nicht das Richtige dabei?

Schreiben Sie uns!

Risk factors for indinavir-associated urological symptoms

Nicht das Richtige dabei?

Zugang & Verfügbarkeit

Vorhandene Bände

Nicht das Richtige dabei?